Delighted to have contributed to the newly launched Redo-TAV app 🚀 ⭐️Coronary Access after Redo-TAV⭐️ 🎯Insights from bench-testing 🎯Key concepts on Coronary Access 🎯Novel techniques & approaches 🎯Leaflet splitting after redo-TAV

Annuloplasty for #treatTR in CIED pat💫 Great abstract by J.Wrobel/M.I.Körber Uniklinik Köln at #DGK2024JT 🎯CIED pat⬆️risk cohort, but successful TTVA possible 🎯lead-caused (vs bystander) TR may limit success ➡️specific pathways incl lead management needed AGIK #PCRonline

Check out our new submission categories JACC Journals #JACCCaseReports with more exciting articles to come: How We Did It, Beyond the Guidelines, Flash Debate, 4 Corners, Mini-Reviews. Dee Dee Wang MD Minnow Walsh, MD, MACC et al Harlan Krumholz

Also s.recent experience Universitätsmedizin Mainz JACC Journals #JACCCVI: Transaxillary JenaValve Technology ➡️Together already @ early stage expanding application of this novel Tx 2 broad range of pat in need #treatAR #focusOnAR 🔗 jacc.org/doi/10.1016/j.… Univ.-Prof. Dr. Ralph Stephan von Bardeleben Philipp Lurz #HTreede

👉 register to the event 💻 watch the live transmission 🗣️ ask your question See you TOMORROW! federica serino Marco Toselli evelina toscano Alessandro Beneduce Arif Khokhar Mamas A. Mamas Valeria Paradies Marta Kaluzna-Oleksy Jonathan Curio Erik Rafflenbeul EAPCIPresident

Dr. Jonathan Curio, et al present the first-in-human #TAVR for pure aortic regurgitation via a transcaval access in a patient with prohibitive alternative arterial accesses. bit.ly/3KrSZVj #JACCCaseReports #vhdAR Jonathan Curio Elmar Kuhn Hendrik Wienemann Matti Adam

🚨 Exciting findings at #NYValves2024! Triplace by Andrea Scotti 🎯 High AV Block in 15% of patients at 1 month after TTVR; 12.4% new PPM 🎯 Most HAVBs (89%) within 1 week from TTVR 🎯 Baseline LBBB/LAFB/LPFB confers a high risk of HAVB Key points: 🔸 Pre-TTVR risk

Insights from the TRI-SPA Registry 🇪🇸 at #NYValves! 🎯Residual TR 0/1+ was associated w/ better functional class and less TR recurrence at 1 year. 🎯Less RV remodeling was observed in patients with nonrecurrent TR. 🎯Recurrent TR was associated w/ worse outcomes at 2 years.

#PCRtricuspid

Very happy to see our first PRIME-MR manuscript on the prognostic impact of residual MR and mean gradient following #TEER for primary #MR published in JACC Journals! Augustin Coisne Benedikt Koell Daniel Kalbacher thomas modine jörg hausleiter Donal t.ly/UuX8i

This year, we will once again be providing the interventional cardiology perspective from #ESCCongress, thanks to contributions from Aaysha Cader A.Nazmi Calik Elad Asher Daniele Giacoppo MIЯVΛƬ #IC Julia Grapsa Jonathan Curio Luis Ortega Paz Panos Xaplanteris and Alessandro Sticchi ! Follow

Hello! Welcome to our 1st (inaugural) issue of JACC Journals #JACCCaseReports on August 7, 2024 under our new editorial board. Congrats to our new Associate Editors and team for making this our largest and most diverse issue ever. See our breadth of articles with links below!

🚨 Final Reminder! Submit by August 25 for #PCRLV to boost your career, expand your network, and get feedback from your peers. Prizes for Best Scientific Abstract, Best Clinical Case, and Best Innovation await. Course Directors dottormaisano, Nicolo Piazza, Bernard Prendergast,

Live from the #ESCCongress in London 🇬🇧 MitrAI score: machine learning models to predict mortality at 12, 24, 36 and 48 months in patients with primary and secondary MR treated by #TEER Read this analysis ✍️ by Jonathan Curio pcronline.com/News/Whats-new… #TMVR #AI